Duality Biotherapeutics, Inc.
9606.HK
Get informed when a big investor buys or sells
+ FollowMarket Cap$16.53B
Close$
Share Statistics
| Market cap | $16.53 Billion |
|---|---|
| Enterprise Value | $14.64 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-38.79 |
| Beta | 1.4 |
| Outstanding Shares | 89,955,392 |
Return
| Return on Equity | -99.16% |
|---|---|
| Return on Assets | -41.02% |
| Return on Invested Capital | -87.46% |
Valuation & Multiples
| P/E Ratio | -9.67 |
|---|---|
| PEG | 17.35 |
| Price to Sales | 18.37 |
| Price to Book Ratio | 10.33 |
| Enterprise Value to Revenue | 17.39 |
| Enterprise Value to EBIT | -9.49 |
| Enterprise Value to Net Income | -11 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.26 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 28, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Duality Biotherapeutics, Inc.
231 employees
CEO: Zhongyuan Zhu Operating as a clinical-stage enterprise, Duality Biotherapeutics, Inc. concentrates on pioneering next-generation antibody-drug conjugate (ADC) therapies and proprietary duality immune toxin antibody conjugate (ITAC) solutions. The firm...